Group 1: Acquisition Overview - The company Yimai Sunshine (02522.HK) announced the acquisition of 70% equity in Guangzhou Gaomai Health Technology Co., Ltd. for a total consideration of 54 million yuan [1] - Following the acquisition, Gaomai Health will become a subsidiary of Yimai Sunshine, and its financial performance will be consolidated into Yimai Sunshine's financial statements [1] - This acquisition is expected to have a significant impact on the third-party medical imaging service industry and the overall healthcare market landscape [1] Group 2: Policy and Market Opportunities - The "One County, One Nuclear Medicine Department" policy aims to enhance the development of nuclear medicine in China, addressing long-standing issues such as insufficient supply of medical isotopes and lack of specialized talent [2] - The National Health Commission has set goals for comprehensive coverage of nuclear medicine departments in hospitals by 2025 and aims for self-supply of major medical isotopes by 2027 [2] - These policies provide strong support and development opportunities for related enterprises in the nuclear medicine sector [2] Group 3: Strategic Significance of the Acquisition - Gaomai Health specializes in nuclear medicine imaging technology and operational management services, which will enhance Yimai Sunshine's capabilities in nuclear medicine project development and management [4] - The acquisition allows Yimai Sunshine to accelerate the establishment of nuclear medicine projects in county-level areas, filling service gaps and improving grassroots healthcare levels [4] - The collaboration is expected to lead to innovative investment and operational models for hospital nuclear medicine projects [4] Group 4: Synergies and Innovations - The partnership will leverage both companies' strengths in radioactive drug development and medical imaging, promoting the application of new radioactive drugs in PET/CT services [5] - This collaboration aims to enhance diagnostic capabilities and provide reliable solutions for early screening and treatment of major diseases [5] - The companies will work together to promote third-party medical imaging services and expand their market presence both domestically and internationally [6] Group 5: Market Dynamics and Competition - The acquisition is seen as a "carrier-level" consolidation in the third-party medical imaging field, increasing market concentration and competitive pressure on smaller firms [7] - The competition will intensify in traditional medical imaging services, with key factors being service quality, pricing, and coverage [7] - Companies will need to innovate business models and enhance their overall strength to navigate the increasingly diverse competitive landscape [7] Group 6: Collaborative Innovation Trends - The acquisition is expected to drive a trend of collaborative innovation within the industry, as companies seek to enhance their competitive edge through partnerships [8] - There will be an increased focus on cooperation with research institutions to accelerate the development of new radioactive drugs [8] - The trend towards "Internet + medical imaging services" will further improve patient experience and service efficiency [8]

自願公告 收購高脈健康股權 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出，以通知本公司股東（「股東」）及本 公司的潛在投資者有關本集團的最新業務發展。 董事會欣然宣佈，於2025年6月22日，本公司全資附屬公司江西贛江新區一脈陽 光健康管理有限公司（「一脈陽光健康管理」）（作為買方）、廣東高尚健康科技集團 有限公司（「賣方I」）、廈門高尚醫學影像診斷中心有限公司（「賣方II」）及合肥高 尚醫學影像診斷中心有限公司（「賣方III」）（作為賣方，統稱為「賣方」）與廣州高 脈健康科技有限公司（「高脈健康」）訂立股權轉讓協議（「股權轉讓協議」），據此， 一脈陽光健康管理將分別向賣方I、賣方II及賣方III收購高脈健康的30.0%、20.0% 及20.0%股權（「收購事項」），總代價為人民幣54,000,000元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi R ...

Summary of Key Points Core Viewpoint - On June 18, 35 Hong Kong-listed companies conducted share buybacks, totaling 26.35 million shares and an aggregate amount of HKD 938 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 990,000 shares for HKD 501 million, with a highest price of HKD 510.00 and a lowest price of HKD 503.50, bringing its total buyback amount for the year to HKD 32.54 billion [1][2]. - AIA Group repurchased 5.21 million shares for HKD 354 million, with a highest price of HKD 68.65 and a lowest price of HKD 67.70, totaling HKD 13.64 billion in buybacks for the year [1][2]. - Techtronic Industries repurchased 250,000 shares for HKD 21.77 million, with a highest price of HKD 87.60 and a lowest price of HKD 86.60, totaling HKD 99.37 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on June 18 was from Tencent Holdings at HKD 501 million, followed by AIA Group at HKD 354 million [1][2]. - In terms of share quantity, the most shares repurchased on June 18 were by Pacific Basin Shipping at 6 million shares, followed by AIA Group and COSCO Shipping at 5.21 million and 5 million shares, respectively [1][2].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年6月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年6月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年6月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

Core Viewpoint - The company, Yimai Sunshine (02522.HK), is experiencing significant trading volume and is committed to long-term value amidst policy support for tiered medical care and AI technology reshaping the healthcare landscape [1][2]. Group 1: Company Overview - Yimai Sunshine has redefined the development path of third-party medical imaging centers in China through a "shared model" and has established a strong competitive moat [1][2]. - The company aims to have over 100 imaging centers nationwide by 2025, covering over 500 institutions and 16 provinces, with a daily addition of 20,000 to 30,000 standardized data cases [2][5]. - The company has developed a significant medical imaging database, being one of the largest in China in terms of data volume and growth rate [2][5]. Group 2: Strategic Partnerships and Innovations - Yimai Sunshine has partnered with Huawei Cloud to enhance AI imaging capabilities, launching the world's first full-modal, full-process medical imaging base model [3]. - Collaborations with various healthcare institutions aim to accelerate the commercialization of AI products and establish Yimai Sunshine as a key player in medical AI [3]. Group 3: Growth Strategies - The company has identified four core growth paths: upgrading thinking, transforming flagship centers, maintaining hospital cooperation value, and penetrating overseas markets [4]. - Yimai Sunshine is exploring new operational models for flagship imaging centers to enhance market penetration and profitability [4]. Group 4: Financial Performance - The company's gross margin increased from 35.8% for the year ending December 31, 2023, to 36.5% for the year ending December 31, 2024, driven by high-margin differentiated products and services [5]. - The company aims to add 1,000 new partners in the future through tiered services and rapid user expansion [5]. Group 5: Addressing Healthcare Challenges - Recent government policies emphasize the sharing of quality medical resources and the promotion of a distributed examination and centralized diagnosis model, which aligns with Yimai Sunshine's operational strategy [6][7]. - The company has implemented a model in Jiangxi that integrates high-end imaging equipment across various medical institutions, facilitating real-time diagnosis by city-level experts [6][7]. Group 6: Market Expansion and Future Outlook - Yimai Sunshine's acquisition of Changsha Zhongya Medical Imaging Diagnosis Co., Ltd. is a strategic move to expand its regional market and build a collaborative network with top hospitals [7]. - The company aims for geometric revenue growth in the next 3-5 years, leveraging accumulated medical imaging data to unlock commercial value [7].

呈交日期： 2025年6月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Core Viewpoint - The acquisition of 100% equity in Changsha Zhongya Medical Imaging Diagnosis Co., Ltd. by Hunan Yimai, a subsidiary of Yimai Sunshine, aims to enhance market position and create synergies in the medical imaging sector in Central China [1][2]. Group 1: Acquisition Details - Yimai Sunshine announced the acquisition of 100% equity in Zhongya Diagnosis for a total price of 29.5 million yuan [1]. - Following the acquisition, Zhongya Diagnosis will become a wholly-owned subsidiary of Hunan Yimai, allowing for the integration of Yimai's product system with Zhongya's business foundation [1][2]. Group 2: Strategic Goals - The acquisition is part of Yimai Sunshine's strategy to leverage its established product offerings and Zhongya's operational strengths to achieve breakthrough performance in the imaging centers [1][2]. - Yimai Sunshine aims to integrate standardized products into existing collaborations with provincial top-tier hospitals, enabling zero customer acquisition costs for revenue generation [2]. Group 3: Company Background and Market Position - Zhongya Diagnosis specializes in early screening and diagnosis of various diseases, including tumors and cardiovascular conditions, and has established long-term partnerships with top hospitals in Hunan [2]. - Yimai Sunshine operates 106 imaging centers across 16 provinces, significantly exceeding competitors in terms of operational scale and regional coverage [3]. Group 4: Management Confidence - The company's management, including the chairman and two executive directors, has committed not to sell shares until December 31, reflecting confidence in the company's future prospects [4].

3. 中国恒大(03333.HK)附属公司委任清盘人，股份自2024年1月29日星期一上午10时18分起暂停买卖， 并将继续停牌，直至另行通知。 4. 市场传闻称泡泡玛特(09992.HK)要进军AI玩具，泡泡玛特相关人士回应称："没听说过"。 5. 一脉阳光(02522.HK)：附属公司湖南一脉拟收购众雅诊断100%股权。 6. 亿纬锂能：拟发行 H 股股票并在香港联合交易所有限公司主板挂牌上市。 7. 龙湖集团(00960.HK)在港交所公告，5月实现总合同销售金额人民币64.7亿元，合同销售面积49.2万平 方米。 金十数据整理：每日港股市场要闻速递（6月10日 周二） 个股新闻： 1. 四环医药(00460.HK)吡洛西利片新增适应症的新药上市申请获受理。 2. 石四药集团(02005.HK)：取得0.3ml马来酸噻吗洛尔滴眼液药品生产注册批件。 ...